A file-set breakdown —
The Pharma Innovation disadvantage says the United States buys the world’s drugs at monopoly prices, those prices fund the research that produces new drugs, and any national health insurance plan that lowers what the government pays collapses the revenue stream that pays for the pipeline. Fewer drugs get made. Biotech loses its lead to China. Then you pick an impact: biodefense, pandemics, antimicrobial resistance, vaccine diplomacy, food security, hegemony, or a US-China war.
The CNDI file explainer states the position more bluntly than most coaches would in front of a judge — frame it through a capitalism-good lens, letting pharma profit-maximize is key to pharma having cash to develop drugs, and astronomical US healthcare costs are the price of everyone getting trickle-down access to new medicine. That is an honest description of what you are defending, and it is why a competent affirmative can turn this into a framing debate.
Thirteen files across four camps. Georgetown has the best link construction and the deepest answer work. CNDI has the perception link and the best-organized affirmative. Michigan is the impact warehouse. Emory is a trimmed teaching version of the Michigan core. What follows is how to deploy the position and how to beat it.
Articulating a Specific Link
Lead with Garthwaite. Georgetown makes it the 1NC link card and CNDI puts it at the front of its link section, and both camps are right. It is the best link evidence in thirteen files and it does three separate jobs.
Garthwaite teaches strategy at Kellogg, he is writing about Medicare for All on the merits for the Aspen Economic Strategy Group, and he concedes most of what the affirmative wants — a single payer really would extract lower prices, and Canadian consumers really do pay roughly 54 percent less for a comparable basket of drugs (Chown et al. 2019). Then he explains why the United States is different, and the explanation is the whole disadvantage: firms make R&D investments against expected global profits, so a country as small as Canada can exercise buyer power without meaningfully changing what gets developed, while the United States cannot because its pricing decisions move the global return. Canada faces a low elasticity of supply of future products. America faces a high one.
Job one is the link. Job two is that it pre-empts the entire “other countries have price controls and still innovate” debate at the level of theory rather than country by country — you win one conceptual point about market share instead of twelve empirical fights about Germany and Denmark.
Job three is the one most debaters miss. Garthwaite is also the answer to CBO. The affirmative’s best defensive card is the CBO estimate that negotiation authority wouldn’t change prices much, and the CNDI file has a version claiming a trillion-dollar hit to profits would derail only eight drugs. Garthwaite explains why CBO says that: the 2007 analysis assumed Medicare could negotiate but not deny access — no closed formulary — so it modeled a buyer with no walk-away power. Give the government a closed formulary and prices fall. Georgetown blocks this out as a standalone AT: CBO card and it is the same paragraph as the link. One card, three functions. Make sure your 2NC knows that.
Cite-check this before you read it. Georgetown cites the paper as Garthwaite 19, dated November 21, 2019, Aspen Economic Strategy Group. CNDI cites the same PDF at the same Kellogg URL as Garthwaite 25. Georgetown’s date looks correct. If you are carrying both files and read the same card under two different years in the same tournament, somebody is going to notice. Pick one and fix the other.
The rest of the link modules, by mechanism:
Single payer. Garthwaite plus the CSWY monopsony block. Cudmore (2020) in the Emory file quantifies exposure — the top five companies draw 40 to 50 percent of revenue from US sales, roughly 70 percent from the US and EU combined, and reinvest 15 to 25 percent of revenue in R&D.
Price controls. Grabowski and Manning (2017): US insurers negotiate in a market setting so prices reflect value delivered, foreign regulators negotiate as monopoly buyers and extract prices near marginal cost, and if every country behaved that way manufacturers could not cover fixed R&D costs.
Public option. Weaker, and know it. The BFHR block gets there in two steps and the affirmative attacks the second. The CNDI affirmative file has a block arguing the disadvantage links to a public option, which they will read against a public option counterplan rather than as defense. If that is your 2NR, read their block first.
Universal catastrophic coverage. Generic substitution alone cuts 40 to 60 percent of pharmaceutical spending, and there is a specialty-drug chain — UCC hits specialty hardest, specialty is where the industry is focused, specialty revenue drives 93 percent of R&D.
Value-based pricing. BFHR has a 1NC and a 2NC. Many affirmatives will call themselves value-based precisely because they think it dodges this.
Deficit spending. Georgetown adds this and I would leave it in the file. The card is a physician blog post on KevinMD that opens by calling single-payer arguments virtue signaling divorced from economic reality. That is not evidence; that is a mood. If you want a spending link, cut a real one.
Contract uncertainty. Georgetown’s version, from Proudman et al. (2024), is the sophisticated one — the hold-up problem. Once R&D investment becomes sunk cost, bargaining power shifts to whoever writes the contract, and rewards can fall well below what justified the investment in the first place. That is a peer-reviewed framing of the same intuition the perception link runs on.
The perception link is CNDI’s contribution and it remains the most important module for this year. The Incubate Coalition investor survey (1/12/26) polled venture firms directly: 87 percent said federal price-setting like MFN would reduce US biotech investment, 74 percent said the IRA’s pill penalty is diverting resources from small molecule development, 81 percent said reduced IP protection would significantly weaken interest. Santerre et al. (2006) adds that the threat of controls changes behavior before any law passes.
The affirmative’s best evidence is backward-looking — the IRA passed and R&D went up. The perception link moves the fight to expectations, where they have no data because the plan hasn’t happened. But note that Georgetown’s affirmative now has an answer, and it is a decent one: Suhonen et al. (2019) argue public procurement reduces market risk because contracts improve the predictability of demand. That is the right response to make, and it means the perception link is contested ground rather than free ground.
The Uniqueness Debate
Your uniqueness evidence is good and it is now consistent across three camps. Georgetown reads Hsu (6/25/26), an OrbiMed general partner, on AI accelerating drug discovery and large pharma’s growing reliance on external innovation, with the GSK acquisition of Nuvalent at $10.6 billion and a 40 percent premium as the proof point. Michigan reads Brown (6/29/26) on the biotech winter thawing. CNDI reads Shivakumar et al. (2024) at CSIS — FDA approvals up 44.5 percent from 2000–2008 to 2009–2017, US firms filing nearly 38 percent of global biotech patents from 2015 to 2020.
The CNDI affirmative file says the opposite with more recent data, and this is still the crux. S&P Global (3/11/26) reports venture-backed funding rounds for US biotech fell 25.2 percent year over year to 237, the lowest since at least 2021, transaction value down to $13.3 billion, and attributes it to drug-pricing reform concerns, NIH funding
pressure, and regulatory restructuring. Fierce Biotech (4/16/26), citing J.P. Morgan, has first-time financings on course for their worst year since before the pandemic — 50 seed and Series A deals worth $2.3 billion in Q1 2026 against 60 worth $3.7 billion a year earlier.
